This short video shares the mechanism of action behind once- weekly Mounjaro. Mounjaro (Tirzepatide) is an injectable medicine that is used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes mellitus. Mounjaro is a class of its own in the treatment of T2DM patients as it is the first and only approved treatment in GLP1/GIP class, which works differently in multiple ways to lower blood glucose from the first dose.
This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
For adverse events and safety reporting, please send an email: [email protected]
For further information, please contact: Eli Lilly and Company, Scientific office O.O Box 92120
Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800
Please go to PDF Material for prescribing information